LLY logo

Eli Lilly and Company

LLY
Healthcare|Drug Manufacturers - General|US
$1354.00
-10.73 (-0.79%)
DCF Value
$771.70
Tangible Book / Share
$13.81
Graham Number
$177.24
Cash / Share
$5.48

Financials

Financial Snapshot

Market Cap
$1273.77B
Enterprise Value
$1318.39B
Revenue (TTM)
$86.46B
Net Income (TTM)
$27.58B
Cash & Investments
$4.88B
Net Cash
-$44.62B
Free Cash Flow (TTM)
$19.66B
Operating CF (TTM)
$30.64B
Debt/Equity
1.23

Cash Runway & Burn Rate

Company is cash-flow positive.

MetricTrend2016201720182019202020212022202320242025TTM
Cash & Investments
$6.04B$8.03B$7.41B$2.44B$3.68B$3.91B$2.21B$2.93B$3.42B$7.27B$4.88B
Operating Cash Flow
$4.85B$5.62B$5.52B$4.84B$6.50B$7.37B$7.59B$4.24B$8.82B$16.81B$30.64B
Free Cash Flow
$3.76B$3.45B$2.51B$3.48B$4.47B$5.39B$4.60B-$3.15B$3.76B$8.97B$19.66B
Capital Expenditure
-$1.09B-$2.16B-$3.02B-$1.35B-$2.03B-$1.98B-$2.99B-$7.39B-$5.06B-$7.84B-$10.98B
Financing Cash Flow
-$559.8M$142.6M-$5.90B-$2.32B-$3.14B-$4.13B-$5.41B$3.50B$1.23B-$2.21B-$5.14B

R&D Spending

R&D (TTM)
$15.38B
R&D Intensity
17.8%
R&D Growth vs Prior
+15.3%
MetricTrend2016201720182019202020212022202320242025TTM
Revenue
$21.22B$19.97B$21.49B$22.32B$24.54B$28.32B$28.54B$34.12B$45.04B$65.18B$86.46B
R&D Expense
$5.31B$5.10B$5.05B$5.59B$5.98B$6.93B$7.19B$9.31B$10.99B$13.34B$15.38B
R&D % of Revenue
25.0%25.5%23.5%25.1%24.4%24.5%25.2%27.3%24.4%20.5%17.8%
SG&A
$6.33B$6.18B$5.73B$6.00B$5.87B$6.14B$6.07B$6.94B$8.59B$11.09B$12.62B

Income Statement

MetricTrend2016201720182019202020212022202320242025TTM
Revenue
$21.22B$19.97B$21.49B$22.32B$24.54B$28.32B$28.54B$34.12B$45.04B$65.18B$86.46B
Cost of Revenue
$5.71B$4.45B$4.68B$4.72B$5.48B$7.31B$6.63B$7.08B$8.42B$11.05B$14.15B
Gross Profit
$15.51B$15.53B$16.81B$17.60B$19.06B$21.01B$21.91B$27.04B$36.63B$54.13B$72.31B
R&D
$5.31B$5.10B$5.05B$5.59B$5.98B$6.93B$7.19B$9.31B$10.99B$13.34B$15.38B
SG&A
$6.33B$6.18B$5.73B$6.00B$5.87B$6.14B$6.07B$6.94B$8.59B$11.09B$12.62B
Operating Income
$3.87B$4.25B$6.03B$6.00B$7.21B$7.93B$8.65B$10.79B$17.04B$29.70B$39.83B
Interest Expense
$185.2M$225.0M$242.5M$400.6M$359.6M$339.8M$331.6M$485.9M$780.6M$795.3M$1.18B
Pretax Income
$3.37B$2.30B$3.68B$5.27B$7.23B$6.16B$6.81B$6.55B$12.68B$25.73B$34.77B
Net Income
$2.74B-$204.1M$3.23B$8.32B$6.19B$5.58B$6.24B$5.24B$10.59B$20.64B$27.58B
EPS (Diluted)
2.49-0.193.138.696.475.856.575.8011.7122.9530.81
EBITDA
$5.06B$4.10B$5.53B$6.90B$8.91B$8.04B$8.66B$8.57B$18.81B$31.69B$44.75B
Shares Out. (M)
1100.881052.021033.67957.53956.59953.65950.18903.28904.06898.00893.40

Balance Sheet

MetricTrend2016201720182019202020212022202320242025TTM
Cash & Equivalents
$4.58B$6.54B$7.32B$2.34B$3.66B$3.82B$2.07B$2.82B$3.27B$7.16B$4.88B
Short-Term Investments
$1.46B$1.50B$88.2M$101.0M$24.2M$90.1M$144.8M$109.1M$154.8M$105.0M$0.00
Total Current Assets
$15.10B$19.20B$20.55B$13.71B$17.46B$18.45B$18.03B$25.73B$32.74B$55.63B$65.26B
Total Assets
$38.81B$44.98B$43.91B$39.29B$46.63B$48.81B$49.49B$64.01B$78.71B$112.48B$148.07B
Total Current Liabilities
$10.99B$14.54B$11.89B$11.78B$12.48B$15.05B$17.14B$27.29B$28.38B$35.23B$47.00B
Long-Term Debt
$8.37B$9.93B$9.20B$13.82B$16.59B$15.35B$14.74B$18.32B$28.53B$40.87B$46.99B
Total Liabilities
$24.73B$33.31B$33.00B$36.59B$40.81B$39.65B$38.71B$53.14B$64.44B$85.94B$107.80B
Stockholders' Equity
$14.01B$11.59B$9.83B$2.61B$5.64B$8.98B$10.65B$10.77B$14.19B$26.54B$40.27B
Retained Earnings
$16.05B$13.89B$11.40B$4.92B$7.83B$8.96B$10.04B$10.31B$13.54B$24.47B$37.97B

Cash Flow Statement

MetricTrend2016201720182019202020212022202320242025TTM
Operating Cash Flow
$4.85B$5.62B$5.52B$4.84B$6.50B$7.37B$7.59B$4.24B$8.82B$16.81B$30.64B
Capital Expenditure
-$1.09B-$2.16B-$3.02B-$1.35B-$2.03B-$1.98B-$2.99B-$7.39B-$5.06B-$7.84B-$10.98B
Free Cash Flow
$3.76B$3.45B$2.51B$3.48B$4.47B$5.39B$4.60B-$3.15B$3.76B$8.97B$19.66B
Investing Cash Flow
-$3.14B-$3.78B$1.91B-$8.08B-$2.26B-$2.87B-$3.76B-$7.15B-$9.30B-$10.97B-$30.41B
Financing Cash Flow
-$559.8M$142.6M-$5.90B-$2.32B-$3.14B-$4.13B-$5.41B$3.50B$1.23B-$2.21B-$5.14B
Issuance of Stock
$0.00$0.00$1.66B$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Repurchase of Stock
-$600.1M-$299.8M-$4.15B-$4.40B-$500.0M-$1.25B-$1.50B-$750.0M-$2.50B-$4.11B-$5.84B
Net Debt Issuance
$2.50B$3.00B-$729.3M$4.69B$291.6M$501.4M-$62.0M$8.65B$8.90B$8.05B$7.32B
Stock Based Comp.
$255.3M$281.3M$279.5M$312.4M$308.1M$342.8M$371.1M$628.5M$645.6M$626.0M$698.1M
Net Change in Cash
$915.7M$1.95B$1.46B-$5.66B$1.32B$161.4M-$1.75B$751.6M$449.8M$4.00B-$4.91B

Dilution Tracker

Shares Outstanding
941M
5-Year Share Growth
-6.1%
Stock Issuance (TTM)
$0.00
MetricTrend2016201720182019202020212022202320242025TTM
Shares Out. (M)
1100.881052.021033.67957.53956.59953.65950.18903.28904.06898.00893.40
Change vs Prior %
—-4.4%-1.7%-7.4%-0.1%-0.3%-0.4%-4.9%0.1%-0.7%-0.5%
Stock Issuance
$0.00$0.00$1.66B$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Stock Repurchase
-$600.1M-$299.8M-$4.15B-$4.40B-$500.0M-$1.25B-$1.50B-$750.0M-$2.50B-$4.11B-$5.84B
Stock Based Comp.
$255.3M$281.3M$279.5M$312.4M$308.1M$342.8M$371.1M$628.5M$645.6M$626.0M$698.1M

Margins & Profitability

MetricTrend2016201720182019202020212022202320242025TTM
Gross Margin %
73.1%77.7%78.2%78.8%77.7%74.2%76.8%79.2%81.3%83.0%83.6%
Operating Margin %
18.2%21.3%28.0%26.9%29.4%28.0%30.3%31.6%37.8%45.6%46.1%
Net Margin %
12.9%-1.0%15.0%37.3%25.2%19.7%21.9%15.4%23.5%31.7%31.9%
EBITDA Margin %
23.8%20.5%25.7%30.9%36.3%28.4%30.3%25.1%41.8%48.6%51.8%
FCF Margin %
17.7%17.3%11.7%15.6%18.2%19.0%16.1%-9.2%8.3%13.8%22.7%
ROE %
19.5%-1.8%32.9%319.1%109.8%62.2%58.6%48.6%74.6%77.8%83.6%
ROA %
7.1%-0.5%7.4%21.2%13.3%11.4%12.6%8.2%13.5%18.4%18.6%
ROIC %
10.6%-0.5%15.6%18.2%18.1%20.4%23.5%19.8%25.7%30.2%30.5%
R&D / Revenue %
25.0%25.5%23.5%25.1%24.4%24.5%25.2%27.3%24.4%20.5%17.8%

Growth (Year over Year)

Fiscal years. Rising share count growth means dilution.

MetricTrend2016201720182019202020212022202320242025
Revenue
6.3%-5.9%7.6%3.8%9.9%15.4%0.8%19.6%32.0%44.7%
Gross Profit
4.0%0.1%8.3%4.7%8.3%10.2%4.3%23.4%35.4%47.8%
Operating Income
7.8%9.8%41.8%-0.4%20.2%10.0%9.1%24.7%58.0%74.3%
Net Income
13.7%-107.5%1683.5%157.4%-25.5%-9.9%11.9%-16.1%102.1%94.9%
EPS (Diluted)
14.2%-107.6%1747.4%177.6%-25.5%-9.6%12.3%-11.7%101.9%96.0%
Operating Cash Flow
63.6%15.8%-1.6%-12.5%34.4%13.3%3.0%-44.1%108.0%90.7%
Free Cash Flow
180.9%-8.2%-27.4%39.0%28.3%20.5%-14.6%-168.5%219.3%138.6%
R&D Expense
10.7%-4.0%-0.9%10.8%6.8%16.0%3.8%29.5%18.0%21.3%
SG&A Expense
-3.1%-2.4%-7.2%4.7%-2.2%4.6%-1.2%14.4%23.8%29.1%
Total Assets
9.1%15.9%-2.4%-10.5%18.7%4.7%1.4%29.3%23.0%42.9%
Book Value / Share
-3.1%-13.3%-4.3%-73.4%116.0%57.6%18.1%6.5%31.2%86.5%
Debt
29.2%32.4%-24.5%53.5%5.0%1.7%-3.8%55.3%33.4%26.3%
Diluted Shares
-0.4%-4.4%-1.7%-7.4%-0.1%-0.3%-0.4%-4.9%0.1%-0.7%

Valuation

P/E (TTM)43.83
10Y Low / Med / High15.12 / 46.58 / 99.99
P/S14.73
10Y Low / Med / High3.82 / 9.30 / 15.44
P/B29.99
10Y Low / Med / High5.78 / 32.64 / 48.99
EV/EBITDA29.46
10Y Low / Med / High17.15 / 31.57 / 63.81
EV/Revenue15.25
10Y Low / Med / High4.09 / 9.76 / 16.11
P/FCF64.79
10Y Low / Med / High21.54 / 47.45 / 184.91

Intrinsic Value Models (per share)

DCF Value
$771.70
Tangible Book / Share
$13.81
Graham Number
$177.24
Cash / Share
$5.48
MetricTrend2016201720182019202020212022202320242025TTM
P/E Ratio
29.54-444.5336.8515.1226.1047.2255.6899.9965.6546.5843.83
P/S Ratio
3.824.455.535.646.589.3012.1815.3615.4414.8114.73
P/B Ratio
5.787.6612.1048.2728.6329.3432.6448.6748.9936.3729.99
EV/EBITDA
17.1523.4222.0420.1919.5734.3841.7763.8138.5831.5729.46
EV/Revenue
4.094.805.676.247.119.7612.6816.0216.1115.3515.25

Analyst Estimates & Quality

Altman Z-Score
9.13
Safe
Piotroski F-Score
7
Strong

Forward Estimates (consensus)

MetricFY2026FY2027FY2028
Revenue$91.10B$106.45B$118.73B
Net Income$31.81B$45.15B$51.47B
EPS$35.33$50.00$57.23
# Analysts (EPS)151510

Dividends

Dividend/Share (TTM)
$6.69
Dividend Yield
0.49%
Frequency
Quarterly
Next Payment
Dec 10, 2026

Recent Payments

Ex-DatePay DateAmountFrequency
Nov 13, 2026Dec 10, 2026$1.73Quarterly
Aug 14, 2026Sep 10, 2026$1.73Quarterly
May 15, 2026Jun 10, 2026$1.73Quarterly
Feb 13, 2026Mar 10, 2026$1.73Quarterly
Nov 14, 2025Dec 10, 2025$1.50Quarterly
Aug 15, 2025Sep 10, 2025$1.50Quarterly
May 16, 2025Jun 10, 2025$1.50Quarterly
Feb 14, 2025Mar 10, 2025$1.50Quarterly
Nov 15, 2024Dec 10, 2024$1.30Quarterly
Aug 15, 2024Sep 10, 2024$1.30Quarterly
May 15, 2024Jun 10, 2024$1.30Quarterly
Feb 14, 2024Mar 8, 2024$1.30Quarterly
Nov 14, 2023Dec 8, 2023$1.13Quarterly
Aug 14, 2023Sep 8, 2023$1.13Quarterly
May 12, 2023Jun 9, 2023$1.13Quarterly
Feb 14, 2023Mar 10, 2023$1.13Quarterly
Nov 14, 2022Dec 9, 2022$0.98Quarterly
Aug 12, 2022Sep 9, 2022$0.98Quarterly
May 13, 2022Jun 10, 2022$0.98Quarterly
Feb 14, 2022Mar 10, 2022$0.98Quarterly

Revenue Segments

By Product

Segment202020212022202320242025
Collaboration and Other Revenue$1.84B$2.36B$3.08B$5.31B$4.29B$4.22B
Product$22.69B$25.96B$25.46B$28.81B$40.75B$60.96B

By Geography

Segment202020212022202320242025
CHINA$1.12B$1.66B$1.45B$1.54B$1.66B$1.95B
Europe$4.19B$4.78B$4.30B$6.17B$6.92B$11.56B
JAPAN$2.58B$2.37B$1.75B$1.67B$1.81B$2.13B
Other Foreign Countries$2.42B—————
UNITED STATES$14.23B$16.81B$18.19B$21.79B$30.38B$43.48B
Non-US—$2.70B$2.85B$2.95B$4.27B$6.06B